Literature DB >> 25906059

Chemotherapy in glioma.

Walter Taal1, Jacoline E C Bromberg, Martin J van den Bent.   

Abstract

The treatment of glial brain tumors begins with surgery, and standard adjuvant treatment at the end of the past millennium for high-grade glioma and high-risk low-grade glioma was radiotherapy and chemotherapy was given at recurrence. However, over the past 10 years much has changed regarding the role of chemotherapy in gliomas and it is now clear that chemotherapy has a role in the treatment of almost all newly diagnosed diffuse gliomas (WHO grade II-IV). This is the result of several prospective studies that showed survival benefit after combined chemoradiotherapy with temozolomide in glioblastoma (WHO grade IV) or after procarbazine, CCNU (lomustine) and vincristine chemotherapy in diffuse low-grade (WHO grade II) and anaplastic (WHO grade III) glioma. The current standard of treatment for diffuse gliomas is described in this overview and in addition some attention is given to targeted therapies.

Entities:  

Keywords:  anaplastic glioma; astrocytoma; chemotherapy; glioblastoma; glioma; high-grade glioma; low-grade glioma; oligoastrocytoma; oligodendroglioma

Mesh:

Substances:

Year:  2015        PMID: 25906059      PMCID: PMC6088309          DOI: 10.2217/cns.15.2

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  79 in total

1.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Authors:  Helen Athanassiou; Maria Synodinou; Evagelos Maragoudakis; Mihalis Paraskevaidis; Cosmas Verigos; Despina Misailidou; Dosia Antonadou; George Saris; Konstantinos Beroukas; Pantelis Karageorgis
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

2.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

3.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

5.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

6.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

7.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

9.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors:  A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

10.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Authors:  M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

View more
  18 in total

1.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

2.  Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.

Authors:  Tiziana Annese; Mariella Errede; Michelina De Giorgis; Loredana Lorusso; Roberto Tamma; Domenico Ribatti
Journal:  Methods Mol Biol       Date:  2023

Review 3.  Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA.

Authors:  Michele Salemi; Maria Paola Mogavero; Giuseppe Lanza; Laura M Mongioì; Aldo E Calogero; Raffaele Ferri
Journal:  Cells       Date:  2022-06-15       Impact factor: 7.666

4.  Is CD147 a New Biomarker Reflecting Histological Malignancy of Gliomas?

Authors:  Xiangyi Kong; Yu Wang; Congxin Dai; Wenbin Ma; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

5.  CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas.

Authors:  Xiangyi Kong; Yu Wang; Shuai Liu; Bing Xing; Yi Yang; Yongning Li; Zuyuan Ren; Changbao Su; Wenbin Ma; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2016-02-16       Impact factor: 5.590

6.  Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.

Authors:  Sheng-Kai Wu; Chia-Lin Tsai; Kullervo Hynynen
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme.

Authors:  Igor S Bryukhovetskiy; Inessa V Dyuizen; Valeriy E Shevchenko; Andrey S Bryukhovetskiy; Polina V Mischenko; Elena V Milkina; Yuri S Khotimchenko
Journal:  Mol Med Rep       Date:  2016-10-13       Impact factor: 2.952

Review 8.  Extracellular Membrane Vesicles as Vehicles for Brain Cell-to-Cell Interactions in Physiological as well as Pathological Conditions.

Authors:  Gabriella Schiera; Carlo Maria Di Liegro; Italia Di Liegro
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

Review 9.  CD34 Over-Expression is Associated With Gliomas' Higher WHO Grade.

Authors:  Xiangyi Kong; Jian Guan; Wenbin Ma; Yongning Li; Bing Xing; Yi Yang; Yu Wang; Jun Gao; Junji Wei; Yong Yao; Zhiqin Xu; Wanchen Dou; Wei Lian; Changbao Su; Zuyuan Ren; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.

Authors:  Antonio Lucena-Cacace; Daniel Otero-Albiol; Manuel P Jiménez-García; Javier Peinado-Serrano; Amancio Carnero
Journal:  Oncotarget       Date:  2017-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.